Concepts (132)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Ovarian Neoplasms | 11 | 2025 | 787 | 1.870 |
Why?
|
| Antibodies, Monoclonal, Humanized | 12 | 2025 | 977 | 1.280 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 11 | 2025 | 2556 | 0.970 |
Why?
|
| Endometrial Neoplasms | 5 | 2023 | 212 | 0.840 |
Why?
|
| Bevacizumab | 5 | 2020 | 270 | 0.840 |
Why?
|
| Genital Neoplasms, Female | 4 | 2020 | 110 | 0.800 |
Why?
|
| B7-H1 Antigen | 3 | 2022 | 286 | 0.780 |
Why?
|
| Vascular Endothelial Growth Factor A | 1 | 2020 | 410 | 0.590 |
Why?
|
| Sirolimus | 3 | 2012 | 175 | 0.520 |
Why?
|
| Maytansine | 2 | 2025 | 12 | 0.460 |
Why?
|
| Antineoplastic Agents | 5 | 2023 | 2368 | 0.450 |
Why?
|
| Radiosurgery | 3 | 2021 | 297 | 0.390 |
Why?
|
| Neoplasm Recurrence, Local | 6 | 2023 | 1398 | 0.380 |
Why?
|
| Neoplasms, Glandular and Epithelial | 1 | 2012 | 76 | 0.370 |
Why?
|
| Postmenopause | 2 | 2007 | 102 | 0.330 |
Why?
|
| Breast Neoplasms | 3 | 2012 | 3054 | 0.320 |
Why?
|
| Endometrium | 2 | 2023 | 50 | 0.320 |
Why?
|
| Carcinoma | 2 | 2011 | 438 | 0.320 |
Why?
|
| Fallopian Tube Neoplasms | 2 | 2024 | 36 | 0.300 |
Why?
|
| Folate Receptor 1 | 2 | 2025 | 3 | 0.290 |
Why?
|
| Genital Diseases, Female | 1 | 2007 | 24 | 0.280 |
Why?
|
| Aged | 15 | 2025 | 19952 | 0.280 |
Why?
|
| Peritoneal Neoplasms | 2 | 2024 | 183 | 0.280 |
Why?
|
| Recombinant Fusion Proteins | 1 | 2009 | 559 | 0.280 |
Why?
|
| Female | 25 | 2025 | 47894 | 0.270 |
Why?
|
| Immunoconjugates | 2 | 2025 | 119 | 0.270 |
Why?
|
| Breast Diseases | 1 | 2007 | 101 | 0.270 |
Why?
|
| Drug Resistance, Neoplasm | 3 | 2025 | 622 | 0.270 |
Why?
|
| Cervix Uteri | 1 | 2007 | 72 | 0.270 |
Why?
|
| Doxorubicin | 3 | 2012 | 296 | 0.260 |
Why?
|
| Antibodies, Monoclonal | 4 | 2022 | 1399 | 0.260 |
Why?
|
| Adenocarcinoma, Clear Cell | 2 | 2023 | 59 | 0.220 |
Why?
|
| Colorectal Neoplasms | 1 | 2012 | 1041 | 0.220 |
Why?
|
| Phosphatidylinositol 3-Kinases | 3 | 2022 | 277 | 0.210 |
Why?
|
| Middle Aged | 13 | 2025 | 27043 | 0.210 |
Why?
|
| Paclitaxel | 1 | 2025 | 495 | 0.200 |
Why?
|
| Patient Reported Outcome Measures | 1 | 2025 | 259 | 0.200 |
Why?
|
| Neoplasms | 4 | 2021 | 3119 | 0.200 |
Why?
|
| Carcinoma, Endometrioid | 1 | 2023 | 51 | 0.200 |
Why?
|
| Quinazolines | 1 | 2023 | 214 | 0.200 |
Why?
|
| Adult | 11 | 2025 | 27535 | 0.190 |
Why?
|
| Indoles | 1 | 2023 | 306 | 0.190 |
Why?
|
| Piperazines | 1 | 2023 | 288 | 0.190 |
Why?
|
| Humans | 25 | 2025 | 92303 | 0.190 |
Why?
|
| Aged, 80 and over | 5 | 2021 | 6916 | 0.160 |
Why?
|
| Angiogenesis Inhibitors | 2 | 2012 | 296 | 0.150 |
Why?
|
| Chemoradiotherapy | 1 | 2020 | 318 | 0.140 |
Why?
|
| Proto-Oncogene Proteins c-akt | 2 | 2025 | 364 | 0.130 |
Why?
|
| Survival Rate | 3 | 2020 | 1927 | 0.110 |
Why?
|
| Class I Phosphatidylinositol 3-Kinases | 2 | 2011 | 67 | 0.110 |
Why?
|
| Poly(ADP-ribose) Polymerase Inhibitors | 2 | 2024 | 76 | 0.110 |
Why?
|
| ras Proteins | 2 | 2011 | 133 | 0.110 |
Why?
|
| Proto-Oncogene Proteins B-raf | 2 | 2011 | 154 | 0.100 |
Why?
|
| Proto-Oncogene Proteins p21(ras) | 2 | 2011 | 170 | 0.100 |
Why?
|
| Neoplasm Metastasis | 4 | 2020 | 1071 | 0.100 |
Why?
|
| Phthalazines | 2 | 2023 | 47 | 0.100 |
Why?
|
| Medical Oncology | 2 | 2024 | 393 | 0.100 |
Why?
|
| Age Factors | 2 | 2007 | 1902 | 0.100 |
Why?
|
| Biomarkers, Tumor | 1 | 2020 | 1576 | 0.100 |
Why?
|
| Antibiotics, Antineoplastic | 1 | 2012 | 112 | 0.090 |
Why?
|
| Maximum Tolerated Dose | 1 | 2012 | 268 | 0.090 |
Why?
|
| Treatment Outcome | 6 | 2021 | 8727 | 0.090 |
Why?
|
| Proto-Oncogene Proteins | 2 | 2011 | 681 | 0.090 |
Why?
|
| PTEN Phosphohydrolase | 1 | 2011 | 143 | 0.090 |
Why?
|
| Drug-Related Side Effects and Adverse Reactions | 1 | 2012 | 205 | 0.080 |
Why?
|
| Neoplasm Staging | 3 | 2024 | 2035 | 0.080 |
Why?
|
| Drug Administration Schedule | 1 | 2011 | 868 | 0.080 |
Why?
|
| Disease-Free Survival | 1 | 2012 | 1180 | 0.080 |
Why?
|
| Mutation | 2 | 2011 | 4210 | 0.080 |
Why?
|
| TOR Serine-Threonine Kinases | 1 | 2011 | 210 | 0.080 |
Why?
|
| Receptors, Vascular Endothelial Growth Factor | 1 | 2009 | 64 | 0.080 |
Why?
|
| Drug Delivery Systems | 1 | 2010 | 183 | 0.070 |
Why?
|
| Protein Kinase Inhibitors | 1 | 2012 | 598 | 0.070 |
Why?
|
| Prognosis | 4 | 2020 | 3872 | 0.070 |
Why?
|
| DNA Probes, HPV | 1 | 2007 | 3 | 0.070 |
Why?
|
| Endometrial Hyperplasia | 1 | 2007 | 11 | 0.070 |
Why?
|
| Uterine Hemorrhage | 1 | 2007 | 21 | 0.070 |
Why?
|
| Dose-Response Relationship, Drug | 1 | 2011 | 1938 | 0.070 |
Why?
|
| Premenopause | 1 | 2007 | 57 | 0.070 |
Why?
|
| Fellowships and Scholarships | 1 | 2008 | 130 | 0.070 |
Why?
|
| Vaginal Smears | 1 | 2007 | 70 | 0.070 |
Why?
|
| Antineoplastic Agents, Immunological | 2 | 2020 | 215 | 0.070 |
Why?
|
| Gynecology | 1 | 2008 | 129 | 0.070 |
Why?
|
| Gynecologic Surgical Procedures | 1 | 2008 | 159 | 0.060 |
Why?
|
| Combined Modality Therapy | 2 | 2021 | 1733 | 0.060 |
Why?
|
| Platinum Compounds | 1 | 2023 | 28 | 0.050 |
Why?
|
| Clinical Trials as Topic | 1 | 2009 | 1150 | 0.050 |
Why?
|
| Dasatinib | 1 | 2023 | 38 | 0.050 |
Why?
|
| Peritoneum | 1 | 2023 | 56 | 0.050 |
Why?
|
| Fallopian Tubes | 1 | 2023 | 46 | 0.050 |
Why?
|
| Risk Factors | 2 | 2019 | 5705 | 0.050 |
Why?
|
| Diphosphates | 1 | 2022 | 18 | 0.050 |
Why?
|
| Ribose | 1 | 2022 | 16 | 0.050 |
Why?
|
| Adolescent | 2 | 2012 | 9491 | 0.050 |
Why?
|
| DNA Mismatch Repair | 1 | 2022 | 58 | 0.050 |
Why?
|
| Estriol | 1 | 2022 | 8 | 0.050 |
Why?
|
| Estrone | 1 | 2022 | 10 | 0.050 |
Why?
|
| Everolimus | 1 | 2022 | 35 | 0.050 |
Why?
|
| Laparoscopy | 1 | 2008 | 767 | 0.050 |
Why?
|
| Epigenomics | 1 | 2022 | 105 | 0.050 |
Why?
|
| Drug Combinations | 1 | 2022 | 206 | 0.050 |
Why?
|
| Ligands | 1 | 2022 | 457 | 0.040 |
Why?
|
| Estradiol | 1 | 2022 | 250 | 0.040 |
Why?
|
| Practice Guidelines as Topic | 1 | 2007 | 1073 | 0.040 |
Why?
|
| Sentinel Lymph Node | 1 | 2019 | 21 | 0.040 |
Why?
|
| Cytoreduction Surgical Procedures | 1 | 2019 | 85 | 0.040 |
Why?
|
| Radiotherapy, Adjuvant | 1 | 2019 | 304 | 0.040 |
Why?
|
| Response Evaluation Criteria in Solid Tumors | 1 | 2018 | 59 | 0.040 |
Why?
|
| Epigenesis, Genetic | 1 | 2022 | 538 | 0.040 |
Why?
|
| Dose-Response Relationship, Radiation | 1 | 2018 | 188 | 0.040 |
Why?
|
| Hysterectomy | 1 | 2019 | 161 | 0.040 |
Why?
|
| Young Adult | 1 | 2010 | 6628 | 0.040 |
Why?
|
| Lymph Node Excision | 1 | 2019 | 225 | 0.030 |
Why?
|
| Chemotherapy, Adjuvant | 1 | 2019 | 485 | 0.030 |
Why?
|
| Radiotherapy Dosage | 1 | 2018 | 475 | 0.030 |
Why?
|
| Male | 4 | 2021 | 43924 | 0.030 |
Why?
|
| Gene Expression Profiling | 1 | 2020 | 1479 | 0.030 |
Why?
|
| Biopsy | 1 | 2018 | 1194 | 0.030 |
Why?
|
| Metaplasia | 1 | 2011 | 37 | 0.020 |
Why?
|
| Receptors, Progesterone | 1 | 2011 | 179 | 0.020 |
Why?
|
| Genetic Predisposition to Disease | 1 | 2019 | 2396 | 0.020 |
Why?
|
| Stem Cell Transplantation | 1 | 2011 | 190 | 0.020 |
Why?
|
| Adenocarcinoma, Mucinous | 1 | 2009 | 48 | 0.020 |
Why?
|
| Taxoids | 1 | 2009 | 126 | 0.020 |
Why?
|
| Cystadenocarcinoma, Serous | 1 | 2009 | 55 | 0.020 |
Why?
|
| Receptors, Estrogen | 1 | 2011 | 401 | 0.020 |
Why?
|
| Receptor, ErbB-2 | 1 | 2011 | 260 | 0.020 |
Why?
|
| Cyclophosphamide | 1 | 2009 | 304 | 0.020 |
Why?
|
| Polymerase Chain Reaction | 1 | 2011 | 923 | 0.020 |
Why?
|
| Drug Therapy, Combination | 1 | 2009 | 807 | 0.020 |
Why?
|
| Data Collection | 1 | 2008 | 379 | 0.020 |
Why?
|
| Retrospective Studies | 1 | 2009 | 9679 | 0.010 |
Why?
|